摘要
目的观察布地奈德雾化吸入治疗特发性肺纤维化(IPF)的疗效和不良反应。方法选择我院收治的IPF患者62例,随机分为观察组和对照组各31例,观察组给予布地奈德雾化液lmg,3次/d,4周后改为布地奈德1mg,2次/d,用8周。对照组给予泼尼松0.50mg/kg口服,1次/d,4周后改为泼尼松0.25mg/kg,口服,用8周,两组患者疗程均为3个月。两组患者的氧疗、化痰等基础治疗相同。比较治疗前、后患者的呼吸困难评分、肺功能、动脉血气分析以及空腹血糖、骨质疏松度等。结果两组患者治疗前及治疗后呼吸困难评分、肺功能、血气分析间差异均无统计学意义(P>0.05)。两组治疗前与治疗后的空腹血糖、骨质疏松度差异均有统计学意义(P<0.05)。结论布地奈德雾化吸入是治疗特发性肺纤维化的有益探索,可以用其代替口服糖皮质激素。
Objective To observe the tberapetutic effects and side effects of aerosolized budesonide to idiopathic pulmonary fibrosis （IPF）, and to discuss the strategies and the related issues. Methods Select 31 cases of IPF patients with budesenide aerosol inhalation and the control group 31 cases, compared the dyspnea score, pulmonary function, blood gas analysis, fasting plasma glucose, osteoporosis degrees between the observer group and the control group before and after treatment. Results Compared with the control group, the dyspnea score, pulmonary function, blood gas analysis in the observer group, there was no significant difference （ P 〉 0. 05）, while the fasting plssma glucose, osteoporosis degrees in the observer group, there was significant difference （ P 〈 0. 05 ）. Conclusion Aerosolized Budesonide to IPF is useful exploration, it can be used to replace oral glucocorticoids.
出处
《实用心脑肺血管病杂志》
2009年第1期31-32,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
